EV/OHPC as a combined injectable contraceptive has a relatively short duration and is associated with a high incidence of menstrual irregularity, for instance polymenorrhea (short and hence fast cycles). This may be unacceptable to many women. Twice-monthly administration of half doses has not been found to improve breakthrough bleeding, though cycle length increased to 20 to 24 days.
Estradiol valerate/hydroxyprogesterone caproate
Estradiol benzoate/hydroxyprogesterone caproate
Testosterone propionate/testosterone enanthate
Estradiol dipropionate/hydroxyprogesterone caproate
Estradiol valerate/testosterone enanthate
Estradiol benzoate/testosterone propionate
Estradiol cypionate/hydroxyprogesterone caproate
Estradiol benzoate/progesterone/testosterone propionate